Introduction
============

Biliary tract carcinomas (BTCs) are invasive adenocarcinomas that arise from the epithelial cells of the biliary tree, which comprises intrahepatic and extrahepatic bile ducts, and gallbladder. Even though BTCs are considered as rare tumors, they represent about 30% of the total primary liver cancers with an incidence rate close to that of hepatocarcinoma. Approximately 1200 new cases in the United Kingdom and 9000 in the United States are diagnosed per year \[[@b1]\]. Unfortunately, only a minority of patients diagnosed with these aggressive tumors present at an early resectable stage, and disease recurrence rates are high despite curative-intent surgery. Prognosis of patients with advanced BTC is extremely poor with overall survival (OS) less than 1 year.

Chemotherapy is a palliative treatment option for patients with advanced disease. Different drugs has demonstrated activity in BTC, including fluoropyrimidines, gemcitabine, cisplatin, and oxaliplatin \[[@b2]--[@b6]\]. A pooled analysis from Eckel et al. \[[@b7]\] including 104 trials with 2810 patients, has established gemcitabine combined with platinum compounds as the provisional standard of chemotherapy in advanced biliary tract cancer.

In 2010, a randomized multicentric phase III ABC-02 trial established the cisplatin/gemcitabine (Gem/CDDP) combination as standard chemotherapy regimen in advanced BTC \[[@b8]\]. The OS was 11.7 months compared to 8.1 months in gemcitabine single agent arm (HR, 0.64; 95% CI, 0.52--0.80; *P* \< 0.001). Different oxaliplatin/gemcitabine (Gemox) combination regimens were assessed in several phase II clinical trials. One randomized study evaluated efficacy of modified gemcitabine and oxaliplatin (mGEMOX) regimen versus best supportive care or fluorouracil and folinic acid (FUFA) regimen. Median OS was 9.5, 4.5, and 4.6 months for mGEMOX, BSC, and FUFA (*P* = 0.039), respectively \[[@b9]\].

Since the ABC-02 trial, Gem/CDDP regimen has become a standard of care in first-line treatment. However, Gemox regimen is a well-established regimen since Sharma\'s study. Furthermore, several clinical randomized trials use Gemox as the comparative arm \[[@b10], [@b11]\]. These two regimens have never been compared. In this context, we carried out this systematic review to obtain an overall descriptive view of efficacy and safety of Gem/CDDP and GEMOX regimens in the first-line chemotherapy treatment of advanced BTC.

Methods
=======

Search for trials
-----------------

Literature searches in PubMed, American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology databases were performed. Searches were limited to human studies and English-language publications. For PubMed database research, the following strategies were used: ("cholangiocarcinoma" OR "biliary tract carcinoma" OR "biliary tract cancer" OR "gall bladder cancer" OR "gall bladder carcinoma") AND (((gemcitabine) AND oxaliplatin) OR ((gemcitabine) AND "cisplatin")). The main keywords used for the search on ASCO and ESMO database are cholangiocarcinoma and chemotherapy.

Selection criteria
------------------

Eligible trials included patients with locally advanced or metastatic biliary tract cancers, defined as tumors of the gallbladder and intrahepatic, perihilar, distal bile ducts, and ampullary tumors. Studies assessed first-line chemotherapy by Gem/CDDP or Gemox.

Data extraction
---------------

Two authors (F. F., M. J. P.) independently extracted information using predefined data abstraction forms. The following details were extracted: type of study, year of publication, study period, number of centers, nationality of the centers, follow-up, eligibility criteria, doses of chemotherapy, treatment schedule, duration of the treatment, patients\' characteristics (age, sex, extent of disease, primary tumor site, WHO-PS, metastatic sites), primary endpoint and its definition, secondary endpoints and their definitions, overall survival (definition, median, and 95% confidence interval), progression-free survival (definition, median, and 95% confidence interval), and grade 3 and 4 toxicity data.

Missing data from studies deemed potentially eligible were sought from the authors via e-mail request. All data were checked for internal consistency, and disagreements were resolved by discussion among the investigators.

Statistical analysis
--------------------

Quantitative data were compared using a Student\'s test or a Mann and Whitney\'s test as appropriate. Qualitative data were compared using chi-square test or Fisher\'s exact test.

Patients characteristics (age, sex, extent of disease, primary tumor site, WHO-PS \>2, metastatic locations) were pooled and compared within each arm.

The primary objective was to assess median of medians overall survival (mOS) and a weighted mOS in studies evaluating Gemox regimens and Gemcitabine/CDDP regimens. The secondary objectives were to assess median of medians progression-free survival (mPFS) and a weighted mPFS, to pool and compare adverse events within each arm. The weighted approach, based on the number of patients included, took into consideration the study size. Thus, larger study contributed more than smaller studies. Toxic effects according to the National Cancer Institute\'s Common Toxicity Criteria for Adverse Events grade 3 and 4 were pooled and compared within each arm.

In order to assess the internal validity of our results, these analyses were repeated 1000 times with the use of bootstrap sample to derive 95% confidence interval for the mOS and mPFS in Gemox and Gemcitabine/CDDP groups.

*P*-value of 0.05 or lower was considered as statistically significant. Analyses were conducted with the use of SAS software, version 9.2 (SAS Institute Inc., Cary, NC), and R software (version 2.10.1).

Results
=======

Characteristics of the studies
------------------------------

Thirty-three studies were included in the review (Fig. [1](#fig01){ref-type="fig"}). Baseline characteristics of the 33 studies are listed in Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. They were published between 2001 and September 2012. Gem/CDDP and Gemox regimens were investigated in 18 and 15 studies, respectively. Among the 18 studies evaluating Gemcitabine/CDDP, two studies were retrospective analyses, 13 studies were single arm phase II trials, two studies were randomized comparative phase II trials, and one study was a phase III trial. Among the 15 studies assessing Gemox, three studies were retrospective analyses, eight studies were single arm phase II trials, three studies were a randomized comparative phase II trials, and one study was a phase III trial. In total, 771 and 699 patients were treated by Gem/CDDP and Gemox, respectively. Table [3](#tbl3){ref-type="table"} pools patients\' characteristics by arms. The only significant difference among available data was the stage of disease: 73% versus 57% metastatic patients in Gem/CDDP and Gemox groups, respectively (*P* \< 0.0001).

###### 

Characteristics of 18 studies assessing combination of cisplatin/gemcitabine.

  First author              Type of study                     Overall patient number   Year of publication   Patients number by arm          Chemotherapy regimen   Dose (mg/m²)   Treatment schedule    Treatment duration
  ------------------------- --------------------------------- ------------------------ --------------------- ------------------------------- ---------------------- -------------- --------------------- --------------------------------
  Carraro \[[@b12]\]        Phase II                          11                       2001                  11                              Cisp + Gem             30 + 1000      d1d8d15/d1d8d15-q4w   NA
  Malik \[[@b13]\]          Phase II                          11                       2003                  11                              Cisp + Gem             70 + 1000      d1/d1d8-q3w           Until DP or UT
  Baluch \[[@b14]\]         Phase II                          14                       2003                  14                              Cisp + Gem             60 + 1000      d1/d1d8-q3w           NA
  Reyes-Vidal \[[@b15]\]    Phase II                          44                       2003                  44                              Cisp + Gem             35 + 1250      d1d8/d1d8-q3w         NA
  Doval \[[@b16]\]          Phase II                          30                       2004                  30                              Cisp + Gem             70 + 1000      d1/d1d8-q3w           Six cycles unless DP or UT
  Thongprasert \[[@b17]\]   Phase II                          43                       2005                  43                              Cisp + Gem             75 + 1250      d1/d1d8-q3w           Until DP or UT
  Kim \[[@b18]\]            Phase II                          29                       2006                  29                              Cisp + Gem             60 + 1250      d1/d1d8-q3w           Until DP
  Giuliani \[[@b19]\]       Phase II                          38                       2006                  38                              Cisp + Gem             80 + 1000      d1/d1d8-q3w           Six cycles unless DP or UT
  Park \[[@b20]\]           Phase II                          27                       2006                  27                              Cisp + Gem             75 + 1000      d1/d1d8d15-q4w        NA
  Lee \[[@b21]\]            Phase II                          24                       2006                  24                              Cisp + Gem             70 + 1000      d1/d1d8-q3w           Until DP or UT
  Meyerhardt \[[@b22]\]     Phase II                          33                       2007                  33                              Cisp + Gem             30 + 1000      d1d8/d1d8-q3w         Until DP or UT
  Charoentum \[[@b23]\]     Retrospective study               42                       2007                  42                              Cisp + Gem             75 + 1250      d1/d1d8-q3w           NA
  Lee \[[@b21]\]            Phase II                          35                       2008                  35                              Cisp + Gem             70 + 1250      d1/d1d8-q3w           Eight cycles
  Valle \[[@b24]\]          Randomized comparative Phase II   86                       2009                  42                              Cisp + Gem             25 + 1000      d1d8/d1d8-q3w         Eight cycles unless DP or UT
  44                        Gem                               1000                     d1d8d15-q4w           Six cycles unless DP or UT                                                                  
  Goldstein \[[@b25]\]      Phase II                          50                       2010                  50                              Cisp + Gem             20 + 1000      d1d8/d1d8-q3w         Until DP or UT
  Okusaka \[[@b26]\]        Randomized comparative Phase II   83                       2010                  41                              Cisp + Gem             25 + 1000      d1d8/d1d8-q3w         Sixteen cycles unless DP or UT
  42                        Gem                               1000                     d1d8d15-q4w           Twelve cycles unless DP or UT                                                               
  Valle \[[@b8]\]           Phase III                         410                      2010                  204                             Cisp + Gem             25 + 1000      d1d8/d1d8-q3w         Eight cycles unless DP or UT
  206                       Gem                               1000                     d1d8d15-q3w           Six cycles unless DP or UT                                                                  
  Weatherly \[[@b27]\]      Retrospective study               85                       2011                  53                              Cisp + Gem             NA             NA                    NA
  32                        "Alternative" regimens            NA                       NA                    NA                                                                                          

DP, disease progression; UT, unacceptable toxicity.

###### 

Characteristics of 15 studies assessing combination of oxaliplatin/gemcitabine.

  First author             Type of study                     Overall patient number   Year of publication   Patients number by arm       Chemotherapy regimen   Dose (mg/m²)   Treatment schedule   Treatment duration
  ------------------------ --------------------------------- ------------------------ --------------------- ---------------------------- ---------------------- -------------- -------------------- ----------------------------
  Gebbia \[[@b28]\]        Phase II                          24                       2005                  24                           Ox + Gem               100 + 1000     d1/d1d8-q3w          NA
  Harder \[[@b29]\]        Phase II                          31                       2006                  35                           Ox + Gem               100 + 1000     d1d15/d1d8d15-q4w    Until DP or UT
  Verderame \[[@b30]\]     Phase II                          24                       2006                  24                           Ox + Gem               100 + 1000     d1/d1d8-q3w          Until DP or UT
  Manzione \[[@b31]\]      Phase II                          34                       2007                  34                           Ox + Gem               100 + 1000     d2/d1-q2w            Until DP or UT
  Kim \[[@b32]\]           Phase II                          40                       2008                  40                           Ox + Gem               100 + 1000     d2/d1-q2w            Until DP or UT
  Andre \[[@b33]\]         Phase II                          70                       2008                  70                           Ox + Gem               100 + 1000     d2/1-q2w             Until DP or UT
  Cassier \[[@b34]\]       Retrospective study               76                       2008                  39                           Ox + Gem               NA             NA                   NA
  26                       Gem                               NA                       NA                    NA                                                                                      
  11                       FU                                NA                       NA                    NA                                                                                      
  Jang \[[@b35]\]          Phase II                          53                       2010                  53                           Ox + Gem               100 + 1000     d1/d1d8-q3w          Until DP or UT
  Hollebecque \[[@b36]\]   Retrospective study               44                       2010                  44                           Ox + Gem               100 + 1000     d2/d1-q2w            Until DP or UT
  Sharma \[[@b37]\]        Phase II                          48                       2010                  48                           Ox + Gem               80 + 900       d1d8/d1d8-q3w        Six cycles unless DP or UT
  Sharma \[[@b9]\]         Randomized comparative Phase II   82                       2010                  26                           Ox + Gem               80 + 900       d1d8/d1d8-q3w        Six cycles unless DP or UT
  27                       BSC                                                                                                                                                                      
  28                       FU + FA                           425 + 20                 d1-q1w                Six cycles unless DP or UT                                                              
  Lee \[[@b32]\]           Phase III                         268                      2011                  133                          Ox + Gem               100 + 1000     d2/d1-q2w            Until DP or UT
  135                      Ox + Gem + erlotinib              100 + 1000 + 100 mg      d2/d1-q2w/daily       Until DP or UT                                                                          
  Fiteni \[[@b38]\]        Retrospective study               44                       2011                  44                           Ox + gem               100 + 1000     d1/d1-q2w            Until DP or UT
  Phelip \[[@b39]\]        Randomized comparative Phase II   34                       2012                  16                           Ox + Gem               100 + 1000     d1/d1-q2w            6 months
  18                       RT-CT                                                                            Until the end of RT                                                                     
  Malka \[[@b40]\]         Randomized comparative Phase II   150                      2012                  74                           Ox + Gem               100 + 1000     d2/d1-q2w            NA
  76                       Ox + Gem + Cetuximab              100 + 1000 + 500         d2/d1/d1-q2w          NA                                                                                      

DP, disease progression; UT, unacceptable toxicity.

###### 

Patient characteristics according to treatment arm.

                                Cisplatin/gemcitabine (*N* = 771)   Oxaliplatin/gemcitabine (*N* = 699)   *P*                                   
  ----------------------------- ----------------------------------- ------------------------------------- ------------- ---- ----- ------------ ----------
  Age-(median in years)         4                                                                         58.15 ± 5.2   4          61.1 ± 5.6   0.1693
  Male sex, *n* (%)             3                                   660                                   353 (53)      3    571   271 (47)     0.03958
  Disease stage                 9                                   437                                                 8    259                
   Locally advanced                                                                                       118 (27)                 111 (43)     
   Metastatic                                                                                             319 (73)                 148 (57)     \<0.0001
  Primary tumor site, *n* (%)   7                                   539                                                 5    496                
   Voie biliaire                                                                                          341 (63)                 327 (66)     
   Vésicuel biliaire                                                                                      179 (33)                 160 (32)     
   Ampoule de vater                                                                                       19 (4)                   9 (2)        0.2108
  WHO-PS-n \>2 (%)              6                                   545                                   4 (0)         6    466   0 (0)        0.1288
  Metastatic sites, *n* (%)                                                                                                                     
   Peritoneal carcinomatosis    14                                  151                                   21 (14)       12   226   27 (12)      0.6369
   Intraperitoneal              12                                  236                                   108 (46)      11   261   133 (51)     0.2809
   Liver                        13                                  193                                   135 (70)      10   283   196 (69)     0.9193
   Lung                         13                                  186                                   25 (13)       10   301   43 (14)      0.8931

![Flowchart showing the progress of trials through the review.](cam40003-1502-f1){#fig01}

Overall survival
----------------

Data on OS were available for 16 studies in Gem/CDDP group and 14 in Gemox group. Individual medians OS and their confidence intervals were plotted for each study within the two groups (Fig. [2](#fig02){ref-type="fig"}A and B).

![Overall survival with (A) cisplatin/gemcitabine and (B) oxaliplatin/gemcitabine.](cam40003-1502-f2){#fig02}

Median of mOS was 9.85 months (ranges: 5--15.2 months) (bootstrap interquartile 95% CI: \[8.6--11\]) in Gemcitabine/CDDP group and 10 months (ranges: 7.5--12.4 months) (bootstrap interquartile 95% CI: \[8.8--11\]) in Gemox group.

Weighted median of mOS was 9.7 months in Gem/CDDP group (bootstrap interquartile 95% CI: \[9--10.5\]) and 9.5 months (bootstrap interquartile 95% CI: \[9.5--10\]) in Gemox group.

Progression-free survival
-------------------------

Data on PFS were available for three studies in Gem/CDDP group and nine in Gemox group. Individual mPFS and their confidence intervals were plotted for each study within the two groups (Fig. [3](#fig03){ref-type="fig"}A and B).

![Progression-free survival with (A) cisplatin/gemcitabine and (B) oxaliplatin/gemcitabine.](cam40003-1502-f3){#fig03}

Median of mPFS was 6.3 months (range: 4--8.5 months) (bootstrap interquartile 95% CI: \[5.8--8\]) in Gemcitabine/CDDP group and 4.9 months (range: 3.4--5.3 months) (bootstrap interquartile 95% CI: \[3.5--8.5\]) in Gemox group.

Weighted median of mPFS was 8 months in Gem/CDDP group (bootstrap interquartile 95% CI: \[8--8\]) and 4.2 months in Gemox group (bootstrap interquartile 95% CI: \[4.2--4.9\]).

Individual data for each study are presented in [Figure 3](#fig03){ref-type="fig"}A and B.

Toxicity
--------

The number of NCI-CTC grade 3 and 4 adverse events was pooled by arms. Patients treated with Gemcitabine/CDDP compared with patients treated with Gemox were more likely to experience asthenia (16% vs. 6%, *P* \< 0.0001), diarrhea (6% vs. 2%, *P* = 0.02919), hepatotoxicity (11% vs. 7%, *P* = 0.04761), anemia (15% vs. 6%, *P* \< 0.0001), thrombopenia (17% vs. 7%, *P* \< 0.0001), and neutropenia (34% vs. 12%, *P* \< 0.0001). On the other hand, oxaliplatin-based chemotherapy caused more peripheral neuropathy than that gemcitabine/CDDP regimens (11% vs. 0%, *P* \< 0.0001) (Table [4](#tbl4){ref-type="table"}).

###### 

Adverse events (grade 3 and 4) according to treatment groups.

                          Cisplatin/gemcitabine (*N* = 771)   Oxaliplatin/gemcitabine (*N* = 699)   *P*                             
  ----------------------- ----------------------------------- ------------------------------------- ---------- ---- ----- --------- ----------
  Asthenia                12                                  381                                   61 (16)    8    408   23 (6)    \<0.0001
  Nausea                  9                                   500                                   23 (5)     10   331   12 (4)    0.5976
  Vomiting                8                                   538                                   26 (5)     6    519   18 (3)    0.2845
  Diarrhea                10                                  266                                   15 (6)     8    373   8 (2)     0.02919
  Peripheral neuropathy   13                                  176                                   1 (0)      3    543   58 (11)   \<0.0001
  Alopecia                14                                  295                                   5 (2)      13   97    0 (0)     0.3388
  Renal toxicity          10                                  424                                   7 (2)      13   97    0 (0)     0.358
  Hepatotoxicity          10                                  451                                   49 (11)    9    360   24 (7)    0.04761
  Anemia                  5                                   608                                   94 (15)    8    300   17 (6)    \<0.0001
  Thrombopenia            3                                   661                                   110 (17)   6    473   34 (7)    \<0.0001
  Neutropenia             4                                   634                                   216 (34)   7    442   52 (12)   \<0.0001
  Mucositis               13                                  165                                   3 (2)      11   241   0 (0)     0.0664
  Febrile neutropenia     12                                  200                                   8 (4)      10   331   13 (4)    1

Sensitivity analysis
--------------------

While the oxaliplatin-based regimens are relatively homogeneous (oxaliplatin dose range 80--100 mg/m^2^), there is marked heterogeneity of the cisplatin--gemcitabine regimens included in the review with variance of the cisplatin doses from low-dose (25--35 mg/m^2^) to high-dose regimens (60--80 mg/m^2^). Therefore, in the sensitivity analysis we assessed the OS, PFS, and toxicity of the Gem/CDDP group by including only the six studies with cisplatin low-dose (25--35 mg/m^2^) administered on days 1 and 8 \[[@b8], [@b14], [@b22], [@b24]--[@b26]\] as in the pivotal phase III ABC-02 trial.

Weighted median of mOS increased from 9.7 to 11.7 months (bootstrap interquartile 95% CI: \[11.2--11.7\]). Weighted median of mPFS was similar to the previous analysis; 8 months in Gem/CDDP group (bootstrap interquartile 95% CI: \[8--8\]).

Patients treated with Gemcitabine/CDDP compared with patients treated with Gemox remained more likely to experience asthenia (16% vs. 6%, *P* \< 0.0001), diarrhea (8% vs. 2%, *P* = 0.004), hepatotoxicity (15% vs. 7%, *P* = 0.0006), anemia (13% vs. 6%, *P* = 0.002), thrombopenia (14% vs. 7%, *P* = 0.043), and neutropenia (29% vs. 12%, *P* \< 0.0001). Peripheral neuropathy rate remained more important in the oxaliplatin-based chemotherapy group (11% vs. 1%, *P* = 0.002) ([Table S1](#SD1){ref-type="supplementary-material"}).

Discussion
==========

Since the randomized multicentric phase III ABC-02 trial, Gem/CDDP combination is considered as the standard first-line chemotherapy in advanced BTC \[[@b8]\]. However, Gemox chemotherapy is frequently preferred as first-line chemotherapy in many cancer institutions and is frequently used in recent clinical trials in association with biotherapies in exploratory studies and as the comparative arms in randomized \[[@b10], [@b11]\]. The reason of choice is based on the easier administration of oxaliplatin than cisplatin requiring hyperhydration and expose to higher risk of renal toxicity. Nevertheless, superiority of one platinum compound over another in this setting was not demonstrated, and there is no clinical trial with direct comparison between different platinum salts in advanced BTC.

This review was conducted following the PRISMA guidelines. It was an exhaustive review including 33 studies (involving 1470 patients) which assessed Gem/CDDP regimen (18 studies involving 771 patients) or Gemox regimen (15 studies involving 699 patients) for advanced BTC. In clinical practice, Gemox and Gem/CDDP are frequently used as first-line therapy in advanced BTC but they have never been compared. A direct statistical comparison was not feasible but to obtain an overall view of comparing efficacy and safety between Gem/CDDP and Gemox regimens, we conducted a descriptive statistical approach by assessing the weighted median of mOS and the weighted median of mPFS. Individual results from each study were presented in forest plots. Weighted median of mOS was 9.7 months in Gem/CDDP group and 9.5 months in Gemox group.

Nevertheless, the oxaliplatin-based regimens are relatively homogeneous (oxaliplatin dose range 80--100 mg/m^2^), but there is marked heterogeneity of the cisplatin--gemcitabine regimens included in the review with variance of the cisplatin doses from low-dose (25--35 mg/m^2^) to high-dose regimens (60--80 mg/m^2^). Therefore, we performed a sensitivity analysis by including only the studies with standard regimen of cisplatin (25--35 mg/m^2^ administered on days 1 and 8) as in the pivotal phase III ABC-02 trial. Interestingly, weighted median of mOS increased from 9.7 to 11.7 months.

Health-related quality of life is a major concern in this palliative setting. Gemox regimen prescribed on day 1 every 2 weeks limits the number of visits compared to the standard regimen of cisplatin (25--35 mg/m^2^ administered on days 1 and 8) as in the pivotal phase III ABC-02 trial. However, the benefit of limited number of visits in terms of quality of life was not demonstrated. Moreover, this analysis indicated that cisplatin-based regimen was associated with a higher incidence of side effects in terms of asthenia, diarrhea, hepatotoxicity, and hematology. Nevertheless, oxaliplatin-based regimen was associated with more peripheral neuropathy which may have more significant detriment on patient quality of life than hematologic toxicity. Furthermore, while there was increased grade 3/4 neutropenia in patient treated with Gem/CDDP group, there was no difference in febrile neutropenia between the regimens. Therefore, the impact of these two regimens on quality of life cannot be clearly analyzed in our study and a longitudinal health-related quality of life analysis is necessary in a prospective randomized trial comparing these two regimens.

Our analysis has some limitations. First, a meta-analysis has not been conducted because these two regimens were never directly compared, so a direct statistical comparison was not feasible. Then, the methodological definitions of primary and secondary outcomes were unspecified in numerous studies. Among the 18 studies assessing Gem/CDDP, 16 trials analyzed the OS but only seven provided criteria defining OS. Among the three studies which analyzed PFS only two studies defined clearly PFS and two trials used the term "time-to-progression" with events of interest "death" and "progression" which is usually the definition of PFS ([Table S2](#SD2){ref-type="supplementary-material"}). Among the 15 studies assessing Gemox, 14 trials analyzed the OS but only eight studies provided criteria defining OS. Among the nine studies which analyzed PFS only five studies defined clearly PFS and one trial used the term "progression-free survival" with events of interest only progression which is usually the definition of time-to-progression ([Table S3](#SD2){ref-type="supplementary-material"}). Then, there is an the imbalance in stage of disease between the two groups with more patients at metastatic setting in the Gem/CDDP group than in the Gemox group, which may impact on toxicity especially hepatotoxicity and asthenia.

Finally, these results suggest that the Gem/CDDP regimen with cisplatin (25--35 mg/m^2^) administered on days 1 and 8 is associated with a short survival advantage than Gemox regimen (11.7 vs. 9.5 months). Our results should be interpreted cautiously and a further confirmatory prospective randomized trial between these two arms taking into account the impact of treatment on health-related quality of life is warranted.
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